ValiRx plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VAL.L research report →
Companywww.valirx.com
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19.
- CEO
- Mark Eccleston
- IPO
- 2002
- Employees
- 16
- HQ
- Hatfield, GB
Price Chart
Valuation
- Market Cap
- $736.72K
- P/E
- -0.41
- P/S
- 14.80
- P/B
- 0.21
- EV/EBITDA
- -0.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -411.15%
- Op Margin
- -4053.35%
- Net Margin
- -3582.56%
- ROE
- -45.91%
- ROIC
- -62.52%
Growth & Income
- Revenue
- $49.77K · 418.49%
- Net Income
- $-1,915,693 · 5.99%
- EPS
- $-0.01 · 27.86%
- Op Income
- $-2,141,671
- FCF YoY
- 21.92%
Performance & Tape
- 52W High
- $0.88
- 52W Low
- $0.18
- 50D MA
- $0.29
- 200D MA
- $0.39
- Beta
- -0.56
- Avg Volume
- 4.65M
Get TickerSpark's AI analysis on VAL.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VAL.L Coverage
We haven't published any research on VAL.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VAL.L Report →